Price T Rowe Associates Inc Ascendis Pharma A/S Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,121,128 shares of ASND stock, worth $264 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
2,121,128
Previous 1,784,148
18.89%
Holding current value
$264 Million
Previous $243 Million
30.16%
% of portfolio
0.04%
Previous 0.03%
Shares
16 transactions
Others Institutions Holding ASND
# of Institutions
243Shares Held
58.8MCall Options Held
250KPut Options Held
377K-
Ra Capital Management, L.P. Boston, MA9.71MShares$1.21 Billion20.22% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.13MShares$639 Million3.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.99MShares$621 Million11.21% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.41MShares$549 Million1.03% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$521 Million0.33% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $6.94B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...